The future for Novo Nordisk A/S’s obesity drug in the Medicare Part D market is getting more complicated. Even if efforts by the company and patient advocates manage to change the law to allow for coverage of Wegovy in Part D, it could face significant price controls once it gets there.
Drugs with obesity as their primary indication are currently excluded from Part D coverage, a prohibition that goes back to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?